1887
Volume 2025, Issue 1
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

The post-COVID-19 syndrome may present with a range of neurological symptoms such as headaches, sleep disorders, and dizziness. The objective of this study was to examine the effectiveness of the Gam-COVID-Vac vaccine in mitigating the neurological symptoms of post-COVID-19 syndrome. The study involved 95 patients diagnosed with the neurological form of long COVID-19, who were divided into two groups according to their vaccination status. The immunological parameters of humoral immunity were evaluated by enzyme-linked immunosorbent assay (ELISA), while the parameters of cellular immunity were evaluated using flow cytometry. Administration of the vaccination resulted in a reduction in clinical symptoms of the neurological form of long COVID-19. Statistically significant differences ( = 0.035) were found in symptoms such as headaches, sleep disturbances, and dizziness, especially in central nervous system (CNS) disorders, between the groups that received the vaccination and those that did not. More than 90% of patients had elevated levels of Receptor Binding Domain (RBD) immunoglobulin G against the viral S-protein (>2,500 BAU/ml), indicating strong humoral immunity regardless of vaccination status. An increase in B-lymphocyte (CD3-CD19+) counts was noted in both groups, with levels significantly higher in the group that received the vaccination ( < 0.03). Analysis of T-cell profiles and NK (natural killer) cell levels showed no changes. The study suggests that administration of Gam-COVID-Vac vaccination could reduce the occurrence of CNS symptoms in individuals with post-COVID-19 syndrome. Although certain neurological symptoms may continue, immunization has a beneficial influence on their progression. The results emphasize the crucial role of an increased humoral immune response in individuals with post-COVID-19 syndrome, but do not show significant changes in T-cell immune parameters.

© 2025 Kurmangaliyeva, Madenbayeva, Urazayeva, Baktikulova, Kurmangaliyev, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.6
2025-02-23
2025-07-17
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/1/qmj.2025.6.html?itemId=/content/journals/10.5339/qmj.2025.6&mimeType=html&fmt=ahah

References

  1. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID19 neurology: Clinical, radiological and laboratory findings. Brain. 2020 Oct 1; 143:(10)3104–3120. doi: 10.1093/brain/awaa240.
     [Google Scholar]
  2. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: A retrospective case series study. JAMA Neurol. 2020 Jun1; 77:(6)683–690. doi: 10.1001/jamaneurol.2020.1127.
     [Google Scholar]
  3. Rudyk DV, Tutchenko MI, Chub SL, Besedinskyi MS. Three cases of fatal postoperative thromboembolic complications in patients with liver cirrhosis and bleeding from esophageal varicose veins after COVID-19. Wiad Lek (Wars Pol 1960).2024 Nov; 77:(8)1627–1632. doi: 10.36740/WLek202408114.
     [Google Scholar]
  4. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020 May;9455–58. doi: 10.1016/j.ijid.2020.03.062.
     [Google Scholar]
  5. Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurol. 2020 Nov; 19:(11)919–929. doi: 10.1016/S1474-4422(20)30308-2.
     [Google Scholar]
  6. Maltsev DV, Hurzhii OO. ANA-associated uveitis in the presence of reactivated HHV-7 infection in a patient with MBL deficiency. Oftalmol Zhur. 2020 Sep; 89:(6)64–69. doi: 10.31288/OFTALMOLZH202066469.
     [Google Scholar]
  7. Cheng Q, Yang Y, Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020 Jun; 56102799. doi: 10.1016/j.ebiom.2020.102799.
     [Google Scholar]
  8. Al Mazrouei SS, Saeed GA, Al Helali AA, Ahmed M. COVID-19-associated encephalopathy: Neurological manifestation of COVID-19. Radiol Case Rep. 2020 Jul7; 15:(9)1646–1649. doi: 10.1016/j.radcr.2020.07.009.
     [Google Scholar]
  9. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020 Sep; 19:(9)767–783. doi: 10.1016/S1474-4422(20)30221-0.
     [Google Scholar]
  10. Krämer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-García R, et al. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021 Nov9; 54:(11)2650–2669.e14. doi: 10.1016/j.immuni.2021.09.002.
     [Google Scholar]
  11. Kowalik MM, Trzonkowski P, Łasińska-Kowara M, Mital A, Smiatacz T, Jaguszewski M. COVID-19 – toward a comprehensive understanding of the disease. Cardiol J. 2020; 27:(2)99–114. doi: 10.5603/CJ.a2020.0065.
     [Google Scholar]
  12. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020 Jul17; 5:(49)eabd6160. doi: 10.1126/sciimmunol.abd6160.
     [Google Scholar]
  13. Fischer B, Lindenkamp C, Lichtenberg C, Birschmann I, Knabbe C, Hendig D. Evidence of long-lasting humoral and cellular immunity against SARS-CoV-2 even in elderly COVID-19 convalescents showing a mild to moderate disease progression. Life (Basel). 2021 Aug9; 11:(8)805. doi: 10.3390/life11080805.
     [Google Scholar]
  14. Tegeler CM, Bilich T, Maringer Y, Salih HR, Walz JS, Nelde A, et al. Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort. Int J Infect Dis. 2022 Jul;120187–195. doi: 10.1016/j.ijid.2022.04.019.
     [Google Scholar]
  15. Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, et al. SARS-CoV-2-specific CD8+T cell responses in convalescent COVID-19 individuals. J Clin Invest. 2021 Mar1; 131:(5)e145476. doi: 10.1172/JCI145476.
     [Google Scholar]
  16. Turmagambetova AS, Sokolova NS, Bogoyavlenskiy AP, Berezin VE, Lila MA, Cheng DM, et al. New functionally-enhanced soy proteins as food ingredients with anti-viral activity. VirusDis. 2015 Oct; 26:(3)123–132. doi: 10.1007/s13337-015-0268-6.
     [Google Scholar]
  17. Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The impact of COVID vaccination on symptoms of long COVID: An international survey of people with lived experience of long COVID. Vaccines (Basel). 2022 Apr21; 10:(5)652. doi: 10.3390/vaccines10050652.
     [Google Scholar]
  18. Massey DB, Krumholz H. Breakthrough symptomatic COVID-19 infections leading to long COVID: Report from long COVID Facebook group poll. medRxiv. 2021 July26. doi: 10.1101/2021.07.23.21261030.
     [Google Scholar]
  19. Mohamed YS, Spaska A, Andrade G, Baraka MA, Ahmad H, Steele S, et al. Hand hygiene knowledge, attitude, and practice before, during and post COVID-19: a cross-sectional study among university students in the United Arab Emirates. Infect Prev Pract. 2024 Mar; 6:(2)100361. doi: 10.1016/j.infpip.2024.100361.
     [Google Scholar]
  20. Clinical Protoco for Diagnostics and Treatment. Coronavirus infection COVID-19. [online]. 2020 Jul 15 [Accessed 16 May 2024]. Available from: https://www.gov.kz/uploads/2020/7/18/4cdd145671895d1bd8e58914117c93dc_original.2463851.pdf .
     [Google Scholar]
  21. Johnson AG, Linde L, Ali AR, DeSantis A, Shi M, Adam C, et al. COVID-19 incidence and mortality among unvaccinated and vaccinated persons aged >/ = 12 years by receipt of bivalent booster doses and time since vaccination – 24 U.S. jurisdictions. MMWR Morb Mortal Wkly Rep. 2023 Feb10; 72:(6)145–152. doi: 10.15585/mmwr.mm7206a3.
     [Google Scholar]
  22. Tremolieres F. Drug treatment for COVID-19 – three years later. Infect Dis Now. 2023 Oct; 53:(7)104761. doi: 10.1016/j.idnow.2023.104761.
     [Google Scholar]
  23. Bocheliuk VY, Spytska LV, Mamicheva OV, Panov MS, Kordonets VV. Psychological Features of Post-COVID Syndrome Course. Int J Health Sci. 2021 Feb; 5:(3)276–285. doi: 10.53730/ijhs.v5n3.1503.
     [Google Scholar]
  24. Andreev AI, Andreev IV, Nechay KO, Esaulova DR, Baklakova OS, Vechorko VI, et al. Correlation between age and the intensity of the post-vaccination humoral immune response in individuals passed COVID-19. Immunol. 2022 Jan; 43:(5)583–592. doi: 10.33029/0206-4952-2022-43-5-583-592.
     [Google Scholar]
  25. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva  AS, et al. Safety and efficacy of an RAD26 and RAD5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb20; 397:(10275)671–681. doi: 10.1016/S0140-6736(21)00234-8.
     [Google Scholar]
  26. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol Spectr. 2021 Sep3; 9:(1)e0034121. doi: 10.1128/Spectrum.00341-21.
     [Google Scholar]
  27. Zaballa ME, Perez-Saez J, de Mestral C, Pullen N, Lamour J, Turelli P, et al. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland. Lancet Reg Health Eur. 2023 Jan; 24100547. doi: 10.1016/j.lanepe.2022.100547.
     [Google Scholar]
  28. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw Open. 2021 Oct1; 4:(10)e2128568. doi: 10.1001/jamanetworkopen.2021.28568.
     [Google Scholar]
  29. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021 Sep; 268:(9)3059–3071. doi: 10.1007/s00415-021-10406-y.
     [Google Scholar]
  30. Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: From neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol. 2020 Aug; 267:(8)2179–2184. doi: 10.1007/s00415-020-09929-7.
     [Google Scholar]
  31. Nakagawara K, Morita A, Namkoong H, Terai H, Chubachi S, Asakura T, et al. Longitudinal long COVID symptoms in Japanese patients after COVID-19 vaccinations. Vaccine: X. 2023 Dec;15100381. doi: 10.1016/j.jvacx.2023.100381.
     [Google Scholar]
  32. Uysal EB, Gümüş S, Bektöre B, Bozkurt H, Gözalan A. Evaluation of antibody response after COVID-19 vaccination of healthcare workers. J Med Virol. 2022 Mar; 94:(3)1060–1066. doi: 10.1002/jmv.27420.
     [Google Scholar]
  33. Castro Dopico X, Ols S, Loré K, Karlsson Hedesta. GB. Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med. 2022 Jan; 291:(1)32–50. doi: 10.1111/joim.13372.
     [Google Scholar]
  34. Swadling L, Maini MK. Can T cells abort SARS-CoV-2 and other viral infections? Int J Mol Sci. 2023 Mar; 24:(5)4371. doi: 10.3390/ijms24054371.
     [Google Scholar]
  35. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021 Oct; 27:(10)1507–1513. doi: 10.1016/j.cmi.2021.05.033.
     [Google Scholar]
  36. Dobrynina MA, Ibragimov RV, Kritsky IS, Verkhovskaya MD, Mosunov AA, Sarapultsev GP, et al. Post-COVID immunopatology syndrome: Characteristics of phenotypical changes in the immune system in post-COVID patients. Med Immunol. 2023 June; 25: (4)791–796. doi: 10.15789/1563-0625-PCI-2707.
     [Google Scholar]
  37. Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, et al. Humoral and T-cell immune response after 3 doses of messenger RNA severe acute respiratory syndrome coronavirus 2 vaccines in fragile patients: The Italian VAX4FRAIL study. Clin Infect Dis. 2023 Feb8; 76:(3)e426–e438. doi: 10.1093/cid/ciac404.
     [Google Scholar]
  38. Dmytriiev D, Dobrovanov O. Post-COVID pain syndrome. Anaesth Pain Intens Care. 2021 Oct; 25:(4)505–512. doi: 10.35975/apic.v25i4.1582.
     [Google Scholar]
  39. Kato Y, Bloom NI, Sun P, Balinsky CA, Qiu Q, Cheng Y, et al. Memory B-cell development after asymptomatic or mild symptomatic SARS-CoV-2 infection. J Infect Dis. 2022 Dec28; 227:(1)18–22. doi: 10.1093/infdis/jiac319 .
     [Google Scholar]
  40. Bongiovanni A, Parisi GF, Scuderi MG, Licari A, Brambilla I, Marseglia GL, et al. Gastroesophageal reflux and respiratory diseases: Does a real link exist? Min Ped. 2019 Jan; 71:(6)515–523. doi: 10.23736/S0026-4946.19.05531-2.
     [Google Scholar]
/content/journals/10.5339/qmj.2025.6
Loading
A comparison of Gam-COVID-Vac vaccination and non-vaccination on neurological symptoms and immune response in post-COVID-19 syndrome
Qatar Medical Journal 2025, 6 (2025); https://doi.org/10.5339/qmj.2025.6
/content/journals/10.5339/qmj.2025.6
/content/journals/10.5339/qmj.2025.6
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): cellular and humoral immunity, coronavirus, damage to the nervous system, hybrid immunity, long COVID-19 and Post-COVID-19

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error